Horizons S&P Financial Select Sector Covered Call ETF HFIN 深 沪
等待开盘 05-15 09:30:00 美东时间
0.00
0.000
NaN.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.00
- 总市值 0
- 52周最高 0.00
- 市盈率 静 --
- 换手率 NaN.00%
- 52周最低 0.00
- 委 比 0.00%
- 总股本 --
- 历史最高 0.00
- 量 比 0
- 振 幅 NaN.00%
- 历史最低 0.00
- 每 手 1
- 风险率
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多GRAIL signals 22%-32% 2026 Galleri sales growth while starting Epic Aura integrations
Earnings Call Insights: GRAIL, Inc. (GRAL) Q1 2026 Management View "This quarter, we saw continued strong commercial momentum with expanding physician adoption, increasing engagement across health sys...
05-06 10:32
BRIEF-HTC Unit Invests $9 Million In KKR Infrastructure Fund Sicav SA
BRIEF-HTC Unit Invests $9 Million In KKR Infrastructure Fund Sicav SA TAIPEI, April 24 (Reuters) - Htc 2498.TW : UNIT H.T.C. (B.V.I.) INVESTS $9 MILLION IN KKR INFRASTRUCTURE FUND SICAV SA UNIT HIGH TECH COMPUTER ASIA PACIFIC PTE. INVESTS $18 MILLION IN ARES PATHFINDER FUND III (OFFSHORE) LP Source
04-24 16:37
GRAIL To Reveal New Data From NHS-Galleri And PATHFINDER 2 At 2026 ASCO Annual Meeting
GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, will present additional data from both the NHS-Galleri trial and the PATHFINDER 2 study further
04-22 04:55
Hims latest offering, Grail's Galleri cancer test, fails U.K. study
GRAIL (GRAL) shares crashed on Thursday in reaction to a failure in a large U.K.-based clinical study for its Galleri multi-cancer screening test, which was added to the Hims & Hers (HIMS) telehealth ...
02-21 02:25
Why Grail Stock Is Sinking Friday
GRAIL (NASDAQ: GRAL) shares plunged after the NHS-Galleri trial failed to meet its primary endpoint. Explore the trial results.
02-20 18:18
GRAIL Announces Topline Results For NHS-Galleri Trial; Primary Endpoint Of Statistically Significant Combined Stage III-IV Reduction Was Not Met
The Primary Endpoint of Statistically Significant Combined Stage III-IV Reduction Was Not Met, However A Favorable Trend Was Observed Over TimeGRAIL Announces U.S. Sales Force Expansion Based on Strong NHS-Galleri and
02-20 05:12
Grail Submits FDA Premarket Approval Application for Galleri Multi-Cancer Early Detection Test
Grail Submits FDA Premarket Approval Application for Galleri Multi-Cancer Early Detection Test GRAIL, Inc. has submitted the final module of its Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for the Galleri® multi-cancer early detection (MCED) test. The Galleri
01-30 08:25
GRAIL Inc. Announces Positive Top-Line Results from PATHFINDER 2 Study, Advancing Galleri® Multi-Cancer Early Detection Test Toward FDA Submission
GRAIL, Inc. has announced that new data from its Galleri® multi-cancer early detection (MCED) test will be presented at the European Society for Medical Oncology (ESMO) Congress in October 2025. The d...
2025-10-04 04:29
BRIEF-Rocket Lab To Launch Electron Mission For European Space Agency’S Next-Generation Navigation System
June 25 (Reuters) - Rocket Lab USA Inc RKLB.O: ROCKET LAB TO LAUNCH ELECTRON MISSION FOR EUROPEAN SPACE AGENCY’S NEXT-GENERATION NAVIGATION SYSTEM ROCKET LAB USA INC - WILL LAUNCH TWO "PATHFINDER A" S...
2025-06-25 17:55
BRIEF-GRAIL Announces Positive Top-Line Results From The Galleri PATHFINDER 2 Registrational Study
June 18 (Reuters) - Grail Inc GRAL.O: GRAIL ANNOUNCES POSITIVE TOP-LINE RESULTS FROM THE GALLERI® PATHFINDER 2 REGISTRATIONAL STUDY GRAIL INC - EXPECTS TO COMPLETE PMA MODULAR SUBMISSION IN FIRST HALF...
2025-06-18 21:24
